What Analyst Projections for Key Metrics Reveal About Steris (STE) Q4 Earnings

Analysts on Wall Street project that Steris (STE) will announce quarterly earnings of $2.58 per share in its forthcoming report, representing an increase of 7.1% year over year. Revenues are projected to reach $1.48 billion, increasing 4.2% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.With that in mind, let's delve into the average projections of some Steris metrics that are commonly tracked and projected by analysts on Wall Street.It is projected by analysts that the 'Revenues- Healthcare' will reach $1.05 billion. The estimate indicates a change of +4.5% from the prior-year quarter.Analysts forecast 'Revenues- Healthcare Products- Service' to reach $360.96 million. The estimate suggests a change of +5.1% year over year.Based on the collective assessment of analysts, 'Revenues- Healthcare Products- Capital equipment' should arrive at $327.37 million. The estimate indicates a change of -1.3% from the prior-year quarter.The average prediction of analysts places 'Revenues- Healthcare Products- Consumables' at $364.74 million. The estimate indicates a year-over-year change of +9.6%.The combined assessment of analysts suggests that 'Revenues- Applied Sterilization Technologies (AST)' will likely reach $269.92 million. The estimate points to a change of +7.6% from the year-ago quarter.Analysts predict that the 'Revenues- Life Sciences' will reach $155.49 million. The estimate suggests a change of -3.2% year over year.Analysts' assessment points toward 'Revenues- Life Sciences- Service' reaching $41.39 million. The estimate suggests a change of -10% year over year.According to the collective judgment of analysts, 'Revenues- Life Sciences- Consumables' should come in at $80.04 million. The estimate indicates a change of +13.7% from the prior-year quarter.Analysts expect 'Revenues- Life Sciences- Capital equipment' to come in at $35.43 million. The estimate indicates a year-over-year change of -19.9%.The consensus estimate for 'Operating income / (loss)- Healthcare' stands at $255.95 million. Compared to the current estimate, the company reported $245.22 million in the same quarter of the previous year.The collective assessment of analysts points to an estimated 'Operating income / (loss)- Applied Sterilization Technologies (AST)' of $118.69 million. Compared to the present estimate, the company reported $114.22 million in the same quarter last year.The consensus among analysts is that 'Operating income / (loss)- Life Sciences' will reach $64.54 million. The estimate is in contrast to the year-ago figure of $64.49 million.View all Key Company Metrics for Steris here>>>Steris shares have witnessed a change of +4% in the past month, in contrast to the Zacks S&P 500 composite's +13.7% move. With a Zacks Rank #2 (Buy), STE is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report STERIS plc (STE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks